Articles Referencing ARQL

Narrower-than-Expected Loss at ArQule - Analyst Blog

5/9/2013, 1:24 pm from Zacks.com in Investing, Business, Stocks

ArQule, Inc. ( ARQL ) recently reported a loss of 9 cents per share in the first quarter of 2013, narrower than the Zacks Consensus Estimate of a loss of 11 cents per share. The company had... Read >>

Data on ArQule's ARQ 092 - Analyst Blog

4/10/2013, 5:10 pm from Zacks.com in Investing, Business, Stocks

Researchers recently presented data on ArQule's ( ARQL ) ARQ 092 at the American Association for Cancer Research (AACR) Annual Meeting held in Washington, D.C. The data revealed that the... Read >>

ArQule Regains ARQ 092 Rights - Analyst Blog

4/2/2013, 6:20 pm from Zacks.com in Investing, Business, Stocks

ArQule, Inc. ( ARQL ) recently announced that the company has regained global rights for the development and commercialization of compounds, which are covered under its AKT collaboration... Read >>

ArQule's Loss Narrower than Expected - Analyst Blog

3/19/2013, 3:48 pm from Zacks.com in Investing, Business, Stocks

ArQule, Inc . ( ARQL ) recently reported a loss of 9 cents per share in the fourth quarter of 2012, narrower than the Zacks Consensus Estimate of 13 cents per share. The company had... Read >>

Synergy Starts SP-333 Phase I Study - Analyst Blog

1/29/2013, 4:50 pm from Zacks.com in Investing, Business, Stocks

Synergy Pharmaceuticals Inc. ( SGYP ) recently initiated a phase Ib study on its inflammatory bowel disease (IBD) candidate, SP-333. SP-333, a guanylate cyclase C (GC-C) agonist,... Read >>

Setback for ArQule, Shares Fall - Analyst Blog

1/14/2013, 1:20 pm from Zacks.com in Investing, Business, Stocks

ArQule Inc. ( ARQL ) and partner Daiichi Sankyo recently announced disappointing phase II results on oncology candidate, tivantinib (ARQ 197). The study evaluated ArQule's lead pipeline... Read >>

Pre-Market Most Active for Jan 11, 2013 : MT, BAC, WFC, NOK, DNDN, BBY, SAP, FB, RIMM, SIRI, AAPL, ARQL

1/11/2013, 8:39 am from NASDAQ.com News in News Headlines, Pre-market Most Active

The NASDAQ 100 Pre-Market Indicator is down -2.35 to 2,741.83. The total Pre-Market volume is currently 2,879,057 shares traded. The following are the most active stocks for the pre-market... Read >>

Neuralstem Is Speculative, But Its Work In Stem Cell Therapy Can't Be Ignored

11/6/2012, 12:15 am from SeekingAlpha in Investing, Stocks

By Smith On Stocks : Introduction I think that the potential of stem cell therapy has captured the imagination of most biotechnology investors who see it as a new potential driver for the... Read >>

Pre-Market Earnings Report for August 2, 2012 : APA, AEE, ANSS, ARIA, APO, ALE, AB, ABMD, AYR, AVD, ARQL, AGEN

8/1/2012, 4:08 pm from NASDAQ.com News in News Headlines, Earnings

The following companies are expected to report earnings prior to market open on 08/02/2012. Visit our Earnings Calendar for a full list of expected earnings releases. Apache Corporation ( ... Read >>

Curtain Closes on ASCO: 2010's Few Winners

6/9/2010, 3:59 am from SeekingAlpha in Investing, Technology

The Burrill Report submits: By Peter Winter In previous years, shares in biotech and pharmaceutical companies have routinely jumped on the release of positive research results at... Read >>

Monday Losers: Delcath, CVS Caremark and Coldwater Creek

6/7/2010, 11:04 am from David Sterman in Investing, Stocks

Among the biggest losers in Monday's early trading are Delcath ( DCTH ) , CVS Caremark ( CVS ) and Coldwater Creek (Nasdaq: CWTR) . Top... Read >>